Literature DB >> 14690459

The diagnostic utility of p63, CK5/6, CK 7, and CK 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas.

Hina S Qureshi1, Adrian H Ormsby, Min W Lee, Richard J Zarbo, Chan K Ma.   

Abstract

BACKGROUND: Distinguishing primary cutaneous adnexal neoplasms (PCANs) from metastatic carcinomas (MCs) can be difficult. We study the utility of p63, CK 5/6, CK 7, and 20 expression in PCAN vs. MC.
METHODS: Twenty-one PCAN with sweat gland differentiation (six benign, 15 malignant), one sebaceous carcinoma, and 15 MC (14 adenocarcinomas, one urothelial carcinoma) to skin were retrieved from the pathology files. Immunostains for p63, CK 5/6, CK 7, and CK 20 were performed and graded as follows: 1, <10; 2, 11-50; and 3 >50% of tumor cells stained.
RESULTS: Twenty of 22 PCAN expressed p63 and CK 5/6. Four of 15 and two of 15 MC were positive for CK 5/6 and p63, respectively. Thirteen of 22 PCAN and 13 of 15 MC were positive for CK 7, respectively. All PCAN were negative for CK 20, two of 15 MC were positive. The sensitivity and specificity for the diagnosis of PCAN were 91 and 73% for CK 5/6, 91 and 100% for p63, and 60 and 13% for CK 7, respectively.
CONCLUSIONS: For distinguishing PCAN from MC: (1) positivity for p63 and CK 5/6 are relatively specific and sensitive for PCAN, (2) CK 7 and 20 are neither sensitive nor specific, and (3) CK 7 positivity in PCAN was focal with a specific pattern in contrast to the diffuse positivity for MC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14690459     DOI: 10.1111/j.0303-6987.2004.00147.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  11 in total

1.  My journey into the world of salivary gland sebaceous neoplasms.

Authors:  Douglas R Gnepp
Journal:  Head Neck Pathol       Date:  2012-03-20

2.  Mohs micrographic surgery in the setting of squamoid eccrine ductal carcinoma: addressing a diagnostic and therapeutic challenge.

Authors:  Shane Clark; Adam Young; Eli Piatigorsky; Larisa Ravitskiy
Journal:  J Clin Aesthet Dermatol       Date:  2013-04

Review 3.  The presentation, pathology, and current management strategies of cutaneous metastasis.

Authors:  Christina Yin Bin Wong; Meghan A Helm; Robert E Kalb; Thomas N Helm; Nathalie C Zeitouni
Journal:  N Am J Med Sci       Date:  2013-09

4.  Expression Patterns of Gli-1, Pleckstrin Homology-Like Domain, Family A, Member 1, Transforming Growth Factor-β1/β2, and p63 in Sebaceous and Follicular Tumors.

Authors:  Su-Young Jeon; Dae-Cheol Kim; Ki-Hoon Song; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2014-11-26       Impact factor: 1.444

5.  Metastatic adnexal cancer in a man.

Authors:  Rashmi Advani; Manhal Izzy; Ashwin Akki; Calley Levine; Nicole Panarelli; Lawrence J Brandt
Journal:  Ann Gastroenterol       Date:  2017-05-12

Review 6.  p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.

Authors:  Artem Smirnov; Lucia Anemona; Flavia Novelli; Cristina M Piro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Int J Mol Sci       Date:  2019-11-17       Impact factor: 5.923

7.  Squamoid eccrine ductal carcinoma of the scalp.

Authors:  Yong-Han Jung; Hye-Jung Jo; Mi-Seon Kang
Journal:  Korean J Pathol       Date:  2012-06-22

8.  Eccrine carcinoma : a rare cutaneous neoplasm.

Authors:  Karima Idrissi Serhrouchni; Taoufiq Harmouch; Laila Chbani; Hind El Fatemi; Mohammed Sekal; Nawal Hammas; Meriem Soughi; Loubna Benchat; Afaf Amarti
Journal:  Diagn Pathol       Date:  2013-02-04       Impact factor: 2.644

9.  A clinicopathological and immunohistochemical correlation in cutaneous metastases from internal malignancies: a five-year study.

Authors:  Sarita Nibhoria; Kanwardeep Kaur Tiwana; Manmeet Kaur; Sumir Kumar
Journal:  J Skin Cancer       Date:  2014-08-25

Review 10.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.